tbuckley/cabot-search huggingface dataset:
SAT-062-Edema index measured by bioelectrical impedance analysis predicts ascites or acute kidney injury after liver resection for hepatocellular carcinoma
Authors: Soon Sun Kim, Gil Ho Lee, So Young Yoon, Bong Wan Kim, Hee Jung Wang, Jung Woo Eun, Chul Won Seo, Hyo Jung Cho, Jae Youn Cheong, Sung Won Cho
Journal: Journal of Hepatology (2019)
THU-295-Non-alcoholic fatty liver disease is associated with QTc lengthening in the general population
Authors: Bubu Banini, Danny Issa, Mulugeta Seneshaw, Mohammad Siddiqui, Abdul Oseini, Faridoddin Mirshahi, Sofanit Dessie, Puneet Puri, Ehimen Aneni, Michael Blaha, Matthew Budoff, Mahmoud Al Rifai, Moyses Szklo, Khurram Nasir, Arun J Sanyal
Journal: Journal of Hepatology (2019)
FRI-334-Cerium oxide nanoparticles present antilipogenic and antiinflammatory effects in rats with diet-induced non-alcoholic fatty liver disease
Authors: Meritxell Perramon Corominas, Silvia Carvajal, Denise Oró, Eudald Casals, Guillermo Fernández Varo, Gregori Casals, Marina Parra-Robert, Jordi Ribera, Manuel Morales-Ruiz, Victor Puntes, Wladimiro Jiménez
Journal: Journal of Hepatology (2019)
NHS trusts pay pension contributions in cash to ease consultants’ tax burden
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Some NHS trusts are seeking to mitigate the impact of high tax bills arising from tighter pension rules by topping up consultants’ salaries with cash.

Changes to rules on pension allowance that limit what staff can save into a pension each year before tax charges apply have landed consultants with huge unexpected tax bills and are causing many to retire early or to avoid taking on additional work.12

The government has acknowledged that the situation is exacerbating the NHS workforce crisis,3 and the health minister Jackie Doyle-Price recently revealed that more than 3500 doctors had retired early from the NHS from 2016 to 2018 because of pension rules.

The Financial Times reported on 14 April4 that around 10 NHS …
THU-473-Role of intracellular lysyl oxidase in progression of primary liver cancer
Authors: Monika Lewinska, Deepak Kumar Bhatt, Letizia Satriano, Douglas VNP Oliveira, Friederike Mahn, Jens Marquardt, Matthias Matter, María Jesús Perugorria, Jesús María Banales, Jesper Andersen
Journal: Journal of Hepatology (2019)
Geriatric preoperative assessment of elderly patients with gastrointestinal cancer: Clinical factors and prognostic implication.
Authors: Catherine Baillargeon, Francine Gaba Idiamey
Journal: Journal of Clinical Oncology (2015)

e20522 Background: Patient selection for surgical oncologic treatment is a challenge, particularly with elderly patients. The purpose of this study was to compare patient's characteristics with geriatrician recommendation as fit or non-fit for surgery and to identify baseline characteristics associated with adverse immediate postoperative outcomes. Methods: We conducted a retrospective study of patients seen in our geriatric oncology clinic before an elective surgical intervention for gastrointestinal cancer between 2010 and 2014. Patients were referred by surgeons or oncologists. Clinical and geriatric assessment variables and postoperative data were collected by chart review. Univariate analyses were used to identify baseline patient's characteristics associated with decision prior to surgery and with postoperative outcomes (length of hospital stay and discharge status). Results: Forty-four patients were included (14 had hepatic metastasis of a colorectal cancer, 13 had rectal cancer, 7 had pancreatic adenocarcinoma, 3 had colon cancer and 7 had other types). Median age was 80.1 years (70-89) and 70% were men. Eleven patients had chemotherapy or radiotherapy before the geriatric assessment. Nine patients (20.5%) were advised against surgery. These patients were more dependent for IADLs (p = 0.003), had lower grip strength ( < 20kg for woman and < 30kg for man) (p = 0.003) and lower gait speed (p = 0.029). Other characteristics were similar between the groups. Twenty-three patients were operated. The median hospital stay was 10 days. Eighteen patients (78%) had complications, 13 minors (Clavien 1-2) and 5 majors (Clavien > 2), including 1 death. Seven patients had delirium. Falls in the last 6 months (p = 0.022) and polypharmacy (p = 0.043) were associated with prolonged hospital stay. Eight patients (36%) were discharged in rehabilitation or convalescent unit, they had lower grip strength (p = 0.019). Conclusions: Low gait speed and grip strength seems to influence preoperative decisions in our geriatric oncology clinic. Falls in the last 6 months, polypharmacy and low grip strength are associated with adverse postoperative outcomes in our study.
Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy
Authors: Jeffrey B. West, Mina N. Dinh, Joel S. Brown, Jingsong Zhang, Alexander R. Anderson, Robert A. Gatenby
Journal: Clinical Cancer Research (2019)

Integration of evolutionary dynamics into systemic therapy for metastatic cancers can prolong tumor control compared with standard maximum tolerated dose (MTD) strategies. Prior investigations have focused on monotherapy, but many clinical cancer treatments combine two or more drugs. Optimizing the evolutionary dynamics in multidrug therapy is challenging because of the complex cellular interactions and the large parameter space of potential variations in drugs, doses, and treatment schedules. However, multidrug therapy also represents an opportunity to further improve outcomes using evolution-based strategies.
FRI-185-Virological and immunological predictors of long-term ouctomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B
Authors: I-Cheng Lee, Chien-Wei Su, Keng-Hsin Lan, Han-Chieh Lin, Ming-Chih Hou, Yi-Hsiang Huang
Journal: Journal of Hepatology (2019)
Should I publish in an open access journal?
Authors: Matthew Kurien, David S Sanders, James J Ashton, R Mark Beattie
Journal: BMJ (2019)

An “author pays” publishing model is the only fair way to make biomedical research findings accessible to all, say <b>Matthew Kurien</b> and <b>David S Sanders</b>, but <b>James J Ashton</b> and <b>R Mark Beattie</b> worry that it can lead to bias in the evidence base towards commercially driven results
Abstract 16557: Safety and Image Quality of the Combined use of Cardiac MRI and the CardioMEMS™ HF System in Progressive PAH; a Proof of Concept Study
Authors: Robert W Biederman, Mark Doyle, Priscilla Correra, Geetha Rayarao, Raymond Benza
Journal: Circulation (2017)

Introduction: Ongoing evaluation of right ventricular (RV) function and ventriculo-vascular coupling (VVC) are fundamental to predicting outcome in pulmonary arterial hypertension (PAH). The Cardio...
SAT-132-Incidence and prognostic factors of de novo development/worsening of esophageal varices in HCV-related compensated advanced chronic liver disease after sustained virological response achieved by direct antiviral agents
Authors: Giulia Tosetti, Pietro Soru, Vincenzo La Mura, Elisabetta Degasperi, Roberta D’Ambrosio, Elena Arsie, Roberta Soffredini, Marta Borghi, Massimo Primignani, Pietro Lampertico
Journal: Journal of Hepatology (2019)
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Authors: Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, Olivier Mir, Nicolas Penel, Nicolas Isambert, Florence Duffaud, Emmanuelle Bompas, Thomas Esnaud, Romain Boidot, Damien Geneste, François Ghiringhelli, Carlo Lucchesi, Carine A. Bellera, François Le Loarer, Antoine Italiano
Journal: Clinical Cancer Research (2019)

CDKN2A loss is frequent in gastrointestinal stromal tumors (GISTs) and associated with aggressive outcome. Palbociclib is a CDK4 inhibitor with preclinical antitumor efficacy in tumors with P16/CDKN2A loss.This is a multicenter single-arm phase II clinical trial assessing safety and efficacy of palbociclib in patients with advanced GIST bearing CDKN2A gene loss. Adults with unresectable locally advanced or metastatic, refractory to at least imatinib and sunitinib, measurable and documented progressive disease (PD) as per RECIST 1.1, and CDKN2A deletion centrally assessed were eligible. Patients received palbociclib 125 mg orally daily on a 21 days on/7 days off dosing schedule, until PD or unacceptable toxicity. The primary endpoint was 4-month non-PD rate according to RECIST 1.1.As of May 2017, 71 patients had been included in the study, and 29 patients (40.3%) met the molecular eligibility requirement. Twenty-five patients (86.2%) had grade 1-2 adverse events (AEs) and 12 patients (41.4%) grade 3-4 AEs possibly related to the drug. The planned interim statistical analysis performed after central histologic and radiological review showed that 19 (86.4%) out of the first 22 evaluable patients had PD at 4 months. CDKN2A status had no impact either on overall survival or outcome on previous standard lines of treatment. Translational analysis suggested upregulation of CCNE1 or downregulation of CDKN1A/P21 or LRRC3B as potential mechanisms of resistance.Palbociclib has no significant clinical activity as a single agent in P16/CDKN2A-deleted GIST refractory to imatinib and sunitinib.
SAT-208-Zinc/Ribavirin: A possible treatment option in chronically HEV genotype 3 infected patients without SVR under ribavirin monotherapy
Authors: Thomas Horvatits, Niels Schübel, Nassim Kamar, Susanne Polywka, Marc Lütgehetmann, Karoline Rutter, Julian Schulze zur Wiesch, Michael P. Manns, Ansgar Lohse, Anne Marie Roque-Afonso, Sven Pischke, Patrick Behrendt, Vincent Mallet
Journal: Journal of Hepatology (2019)
Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder
Authors: Ylva Kaiser, Anders Eklund, Johan Grunewald
Journal: European Respiratory Journal (2019)

Despite more than a century of research, the causative agent(s) in sarcoidosis, a heterogeneous granulomatous disorder mainly affecting the lungs, remain(s) elusive. Following identification of genetic factors underlying different clinical phenotypes, increased understanding of CD4 + T-cell immunology, which is believed to be central to sarcoid pathogenesis, as well as the role of B-cells and other cells bridging innate and adaptive immunity, contributes to novel insights into the mechanistic pathways influencing disease resolution or chronicity. Hopefully, new perspectives and state-of-the-art technology will help to shed light on the still-elusive enigma of sarcoid aetiology. This perspective article highlights a number of recent advances in the search for antigenic targets in sarcoidosis, as well as the main arguments for sarcoidosis as a spectrum of autoimmune conditions, either as a result of an external (microbial) trigger and/or due to defective control mechanisms regulating the balance between T-cell activation and inhibition.
The Fragility Index—<i>P</i> Values Reimagined, Flaws and All
Authors: Sergio A. Acuna, Colin Sue-Chue-Lam, Fahima Dossa
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
A Modern Snapshot of the Daily Work of Medical Interns—The Burden of Indirect Patient Care
Authors: Christopher Moriates, F. Parker Hudson
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Why do cancer patients who are already on treatment transfer their care to another facility?
Authors: Douglas Kelly, Laurence Altshuler
Journal: Journal of Clinical Oncology (2015)

e20568 Background: Cancer patients who are already undergoing treatment will sometimes seek a second opinion or transfer their care to a different facility. Are these transfers due to random causes such as insurance change, relocation or dissatisfaction with a provider, or are they due to disease triggers such as cancer progression, limited treatment options, or a worsening quality of life? We surveyed patients to assess this. Methods: Patients were eligible if they were consulting at SRMC for the first time, but had already started cancer treatment elsewhere, consisting of surgical resection, radiation, and/or chemotherapy. One hundred consecutive eligible patients who agreed to participate were enrolled. The intake physician assessed the patient’s current disease status, treatment history, and performance status. The patient completed the EQ-5D-5L quality of life tool and a survey asking whether there were any recent changes that prompted the patient to come to this hospital. Results: Based on physician assessment, 73% of patients had previously experienced relapse or progression. 88% had locally advanced or metastatic cancer. On the most recent radiology reports, 87% had worsening disease. On the patient survey, 88% had complaints of recent disease progression or limited treatment options. 69% had complaints of recent worsening symptoms or quality of life. 64% had concerns with both disease status and symptoms, and only 7% had neither complaint. The 7% with no complaints tended to still be in the first course of treatment (5/7), and have a good quality of life (6/7). Conclusions: When cancer patients have already started treatment and then seek a second opinion or transfer of care, 93% of the patients perceive a recent worsening of disease, lack of treatment options, or worsening quality of life. This supports the hypothesis that these are the motivating forces behind cancer patients transferring care rather than non-disease related causes.
Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay.
Authors: Maria E. Arcila, Helena Alexandra Yu, Alexander E. Drilon, Gregory J. Riely, Ahmet Zehir, Justyna Sadowska, David Michael Hyman, Mark G. Kris, Michael F. Berger, Marc Ladanyi
Journal: Journal of Clinical Oncology (2015)

e22160 Background: Genotyping is central to the management of patients with lung adenocarcinoma (LUAD). Complete assessment for all clinically relevant genomic alterations can be challenging given the large proportion of patients presenting with advanced disease and only small biopsy (bx) specimens available. Comprehensive upfront testing for all relevant genomic alterations in a single assay offers multiple advantages. We describe our experience using a clinically validated NGS assay to concurrently detect relevant mutations, copy number alterations and rearrangements. Methods: We used a hybrid-capture based NGS assay (MSK-IMPACT) to detect somatic alterations (point mutations, indels, copy number changes and select structural rearrangements) in 341 genes. Consecutive cytologic and small bx LUAD samples received for routine analysis over a 10 month period are included. Unstained slides received per case ranged from 15-20 (5um each). Corresponding H&E stained slides were reviewed and cell counts performed in a subset to establish minimal tissue requirements. Samples were sequenced (Illumina HiSeq 2500) and analyzed with a custom analysis pipeline as tumor/normal pairs. Results: A total of 224 LUAD samples were received. 172 (77%) were defined as limited tissue (133 needle bx, 38 FNA's prepared in cell blocks) of which 89% (153/172) were successfully tested and 19 (11%, 19/172) failed due to low tumor content or low DNA yield. Cell counts for failed samples averaged 239 cells / slide (range 10-270) while all successfully tested had over 1,000 cells each. Failure rate was similar for cytology and small biopsies (13% vs 11%). Among 116 EGFR / ALK WT cases, MSK-IMPACT uncovered targetable genomic alterations that would have remained undetected through focused EGFR /ALK testing alone including mutations in HER2 (9) and BRAF (7) and fusions involving ROS1 (4) and RET (3). Conclusions: Comprehensive hybrid-capture based NGS assays such as MSK-IMPACTare a highly efficient testing strategy for LUAD, providing assessment for all driver oncogenes even in cases with limited material, and allowing timely choice of therapy.
FRI-124-Increased prevalence of low-frequency and rare NOD2 variants in patients with liver cirrhosis
Authors: Matthias Reichert, Cristina Ripoll, Markus Casper, Paul Horn, Tony Bruns, Frank Grunhage, Robin Greinert, Beate Appenrodt, Alexander Zipprich, Frank Lammert
Journal: Journal of Hepatology (2019)
Familial Pulmonary Fibrosis and Hermansky-Pudlak Syndrome Rare Missense Mutations in Context
Authors: Robert S. Stearman, Amber R. Cornelius, Lisa R. Young, David S. Conklin, Elizabeth A. Mickler, Xiao Lu, Naoko Hara, Lynsey M. Fettig, Tzu L. Phang, Mark W. Geraci
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
THU-118-Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study
Authors: Sofia Bartlett, Stanley Wong, Amanda Yu, Maria Alvarez, Terri Buller-Taylor, Zahid A Butt, Maryam Darvishian, Carmine Rossi, Mawuena Binka, Dr. Margo Pearce, Dr. Jason Wong, Dr. Mark Gilbert, Mark Tyndall, Mel Krajden, Naveed Janjua
Journal: Journal of Hepatology (2019)
PS-079-HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy
Authors: Christine Y.L. Tham, Janine Kah, Anthony Tan, Alessandro Loglio, Camille Sureau, Marc Lütgehetmann, Pietro Lampertico, Maura Dandri, Antonio Bertoletti
Journal: Journal of Hepatology (2019)
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Authors: C.G. Kim, K.H. Kim, K.-H. Pyo, C.-F. Xin, M.H. Hong, B.-C. Ahn, Y. Kim, S.J. Choi, H.I. Yoon, J.G. Lee, C.Y. Lee, S.Y. Park, S.-H. Park, B.C. Cho, H.S. Shim, E.-C. Shin, H.R. Kim
Journal: Annals of Oncology (2019)
Use of a Dynamic Genetic Testing Approach for Childhood-Onset Epilepsy
Authors: Jorune Balciuniene, Elizabeth T. DeChene, Gozde Akgumus, Edward J. Romasko, Kajia Cao, Holly A. Dubbs, Surabhi Mulchandani, Nancy B. Spinner, Laura K. Conlin, Eric D. Marsh, Ethan Goldberg, Ingo Helbig, Mahdi Sarmady, Ahmad Abou Tayoun
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Although genetic testing is important for bringing precision medicine to children with epilepsy, it is unclear what genetic testing strategy is best in maximizing diagnostic yield. <h3>Objectives</h3> To evaluate the diagnostic yield of an exome-based gene panel for childhood epilepsy and discuss the value of follow-up testing. <h3>Design, Setting, and Participants</h3> A case series study was conducted on data from clinical genetic testing at Children’s Hospital of Philadelphia was conducted from September 26, 2016, to January 8, 2018. Initial testing targeted 100 curated epilepsy genes for sequence and copy number analysis in 151 children with idiopathic epilepsy referred consecutively by neurologists. Additional genetic testing options were offered afterward. <h3>Exposures</h3> Clinical genetic testing. <h3>Main Outcomes and Measures</h3> Molecular diagnostic findings. <h3>Results</h3> Of 151 patients (84 boys [55.6%]; median age, 4.2 years [interquartile range, 1.4-8.7 years]), 16 children (10.6%; 95% CI, 6%-16%) received a diagnosis after initial panel analysis. Parental testing for 15 probands with inconclusive results revealed de novo variants in 7 individuals (46.7%), resulting in an overall diagnostic yield of 15.3% (23 of 151; 95% CI, 9%-21%). Twelve probands with nondiagnostic panel findings were reflexed to exome sequencing, and 4 were diagnostic (33.3%; 95% CI, 6%-61%), raising the overall diagnostic yield to 17.9% (27 of 151; 95% CI, 12%-24%). The yield was highest (17 of 44 [38.6%; 95% CI, 24%-53%]) among probands with epilepsy onset in infancy (age, 1-12 months). Panel diagnostic findings involved 16 genes:<i>SCN1A</i>(n = 4),<i>PRRT2</i>(n = 3),<i>STXBP1</i>(n = 2),<i>IQSEC2</i>(n = 2),<i>ATP1A2</i>,<i>ATP1A3</i>,<i>CACNA1A</i>,<i>GABRA1</i>,<i>KCNQ2</i>,<i>KCNT1</i>,<i>SCN2A</i>,<i>SCN8A</i>,<i>DEPDC5</i>,<i>TPP1</i>,<i>PCDH19</i>, and<i>UBE3A</i>(all n = 1). Exome sequencing analysis identified 4 genes:<i>SMC1A</i>,<i>SETBP1</i>,<i>NR2F1</i>, and<i>TRIT1</i>. For the remaining 124 patients, analysis of 13 additional genes implicated in epilepsy since the panel was launched in 2016 revealed promising findings in 6 patients. <h3>Conclusions and Relevance</h3> Exome-based targeted panels appear to enable rapid analysis of a preselected set of genes while retaining flexibility in gene content. Successive genetic workup should include parental testing of select probands with inconclusive results and reflex to whole-exome trio analysis for the remaining nondiagnostic cases. Periodic reanalysis is needed to capture information in newly identified disease genes.
TCTAP A-056 Effect of Selected Antioxidants on VEGFR-2 Expression and Vasculogenesis in 48-hour Age Chick Embryo
Authors: Indriati Dwi Rahayu, Eliana Susilowati, Nadia Ovianti, Birgitta Stella Dewi Hamzah, Rita Rosita, Muhammad Wildanulhaq, Irfan Allan, Fakhmi Kartika Yudha
Journal: Journal of the American College of Cardiology (2019)